A “Do It Better” Challenge: Can You Improve Outcomes for Patients With Obesity and Type 2 Diabetes?

Here’s my take on why it’s important to address weight loss for reducing the risk of comorbidities in patients with type 2 diabetes and the role of GLP-RAs and SGLT2 inhibitors in amplifying a healthier lifestyle.

Carol Hatch Wysham, MD Released: September 14, 2022

Here’s my take on the inclusion of a dual GIP/GLP-1 receptor agonist in the therapy selection decision-making process for patients with T2D, considering both their comorbidities and their priorities.

Carol Hatch Wysham, MD Released: October 5, 2022

Here’s my take on strategies to collaborate with patients on their journey to achieve their weight loss goals.

Jennifer Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM Released: November 2, 2022